AFP and animal viral hepatitis: For treatment outcomes to immunotherapy, the clinico-pathological characteristics in patients which correlated with preferable PFS were BCLC B disease, viral hepatitis positivity, AFP less than 400 ng/ml, EHS/MVI, and prior local therapy.